In:
Current Radiopharmaceuticals, Bentham Science Publishers Ltd., Vol. 16, No. 3 ( 2023-09), p. 243-252
Abstract:
Previously, low-dose radiation therapy was
used for pneumonia treatment. We aimed to investigate the safety and effectiveness of carbon nanoparticles labeled with Technetium
isotope (99mTc) in a form of ultradispersed aerosol in combination with standard COVID-19 therapy. The study was a randomized
phase 1 and phase 2 clinical trial of low-dose radionuclide inhalation therapy for patients with COVID-19 related pneumonia. Methods: We enrolled 47 patients with confirmed COVID-19 infection
and early laboratory signs of cy tokine storm and randomized
them into the Treatment and Control groups. We analyzed blood parameters reflecting the COVID-19 severity and inflammatory
response. Results: Low-dose 99mTc-labeled inhalation showed a minimal
accumulation of radionuclide in lungs in healthy volunteers. We observed no significant differences between the groups before
treatment in WBC-count, D-dimer, CRP, Ferritin or LDH levels. We found that Ferritin and LDH levels significantly raised after the
7th day follow-up only in the Control group (p 〈 0.0001 and p =
0.0005, respectively), while mean values of the same indicators did not change in patients in the Treatment group after the radionuclide
treatment. D-dimer values also lowered in the radionuclide treated group, however, this effect was not statistically significant. Furthermore,
we observed a significant decrease in CD19+ cell counts in patients of the radionuclide-treated group. Conclusion: Inhalation low-dose radionuclide therapy of 99mTc
aerosol affects the major prognostic indicators of COVID-19- related pneumonia restraining inflammatory response. Overall, we
identified no evidence of major adverse events in the group receiving radionuclide.
Type of Medium:
Online Resource
ISSN:
1874-4710
DOI:
10.2174/1874471016666230307113045
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2023